NCT07020065View on ClinicalTrials.gov

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions
Metastatic NSCLC - Non-Small Cell Lung Cancer
Interventions
DRUG

Cemiplimab

cemiplimab IV 350 mg, day 1

DRUG

Carboplatin

carboplatin IV AUC 3 day 1

DRUG

Pemetrexed & Gemcitabine

pemetrexed IV 300 mg/m2 day 1 gemcitabine IV 600 mg/m2 day 1, d8

DRUG

Paclitaxel

paclitaxel IV 50 mg/m2 day 1, d8

Trial Locations (16)

1211

Hôpitaux Universitaires de Genève, Geneva

1752

HFR Fribourg, Fribourg

1951

Hôpital du Valais - Sion, Sion

3010

Inselspital, Bern

4031

Universitätsspital Basel, Basel

4101

Kantonsspital Baselland, Bruderholz

4600

Kantonsspital Olten - Solothurner Spitäler, Olten

5404

Kantonsspital Baden, Baden

6962

EOC Istituto Oncologico della Svizzera Italiana (IOSI), Viganello

8063

Stadtspital Zürich Triemli, Zurich

8401

Kantonsspital Winterthur, Winterthur

KSW Kantonsspital Winterthur, Winterthur

8501

Spital Thurgau AG - Kantonsspital Frauenfeld, Frauenfeld

CH-5001

Kantonsspital Aarau, Aarau

CH-7000

Kantonsspital Graubuenden, Chur

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER